Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.

Cardinal Health receives a Buy rating, supported by defensive business fundamentals, strong adjusted EPS growth, and strategic expansion into specialty healthcare. CAH's Q3FY26 showed 11% revenue growth and 35% adjusted EPS growth, though GAAP results were pressured by higher costs and special items. Valuation is at a premium with a Forward P/E of 21.64x, justified by improving profitability and cash flow, but future upside depends on sustained margin gains.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Cardinal Health (CAH) closed at $237.92 in the latest trading session, marking a +1.35% move from the prior day.

Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

In the latest trading session, Cardinal Health (CAH) closed at $233.01, marking a +1.79% move from the previous day.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Cardinal Health has gained nearly 8% in 2026 as specialty pharma growth, rising EPS, and expanding healthcare services fuel investor optimism.